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1. Introduction 
Indolizidine and quinolizidine are prominent heterobicyclic 
compounds containing a bridgehead nitrogen atom (Figure 1). 
These frameworks are often present in alkaloids isolated from 
diverse natural sources, frequently as part of a more c mplicated 
polyheterocyclic structure.1 The polyhydroxylated indolizidines 
derived from plants and fungi, which function as potent 
glycosidase inhibitors, and the alkylindolizidines isolated from 
the skin of amphibians are among the most investigated groups of 
simple indolizidines. Prototypical examples of the first group are 
swainsonine and castanospermine, which have demonstrated 
activity against the HIV and other viruses,2 stimulating 
considerable research on the synthesis of related structures and 
their mode of action. For instance, the castanospermin  
derivative known as celgosivir is currently in clinical trials as an 
anti-AIDS agent and for the treatment of dengue infections.3 (−)-
Lupinine and (−)-sparteine, isolated from plants, are probably the 
most representative examples among simple quinolizidines,4 
while 1,4- and 4,6-disubstituted quinolizidines are the more 
common structural patterns found in amphibian skin.5 Bioactivity 
studies on quinolizidine alkaloids are relatively scarce, although 
some promising findings have been reported. For example, 
clavepictines A and B, isolated from a marine inverteb ate, 
exhibit antimicrobial, antifungal, and antitumor activity.6 The 
detailed structural assignment and biological evaluation of some 
isolated indolizidine and quinolizidine alkaloids is often 
constrained by affordability problems and, therefor, many 
investigations have been devoted to developing synthetic 
approaches to these systems.7 In the last years, the interest in 
these heterobicycles has been expanded to the field of 
peptidomimetics. The replacement of a dipeptide motif with a 
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constrained or rigidified counterpart that simulates a β-turn in 
the packaging of polypeptides has become a useful strategy for 
developing new therapeutic agents.8 For instance, IBTM is an 
indolizidine dipeptide surrogate widely used to generate 
conformationally constrained β-turn mimics9 and several analogs 
of it have been synthesized and investigated, showing d verse 
biological activities.10 In this context, innovative methodologies 
for the synthesis of indolizidine and quinolizidine systems have 
been described,11 wherein the regio- and stereochemical control 
of the substituent attachment is a main issue. Some f the 
described syntheses include alkylation reactions of cyclic 
iminium ions, mainly intramolecular,12 and other encompass a 
ring closing metathesis (RCM) reaction.13 However, there are 
only a few examples wherein these two processes were combined 
to generate one of these azabicycles,14 and the asymmetric 
versions rely on chiral pool starting materials.14a,c 
In former investigations, we adapted the palladium-catalyzed 
asymmetric allylic alkylation (AAA) of phtalimide developed by 
Trost15 to the preparation of the N-subtituted succinimide (+)-5 
and glutarimide (+)-6 (Scheme 1), which were used as starting 
materials for the synthesis of polycyclic alkaloids of the 
Securinega family.16 Along these investigations, the tert-
butyldiphenylsilylsilyl ethers derived from (+)-5 and (+)-6 were 
respectively reduced to the corresponding acylaminals (1’R)-7 
and (1’R)-8, as precursors of the acyliminium ions 9 and 10 that 
were then involved in a vinylogous Mannich reaction. Herein we 
describe how the AAA of succinimide and glutarimide canbe an 
efficient entry to the enantioselective synthesis of indolizidine 
and quinolizidine frameworks, respectively, the N-acyliminium 
ions 9 and 10 acting as templates for the construction of these 
azabicyclic systems. An application of our strategy to the 
synthesis of indolizidine dipeptides is also reported. 
 
2. Results and discussion 
Our plan consisted on generating the N-acyliminium ions 9 or 
10, with a specific configuration of its stereogenic center, in the 
presence of an allylating reagent. This operation should furnish 
the dienes 11/12 containing a second stereogenic center. Then, a 
ring closing metathesis (RCM) reaction would provide the 
second ring. 
The study was initiated by using the N-acylaminal (1’S)-7, 
readily prepared from succinimide through the sequence in 
Scheme 1 employing (R,R)-4 as the chiral ligand. In the allylation 
of aminals, the Lewis acid exerts a fundamental effect on the 
formation of the electrophilic N-acyliminium ion and it also 
promotes the nucleophilic attack of the allylating reagent to this 
cation.17 After exploring several combinations of Lewis 
acid/solvent/temperature, we found that treatment of (1’S)-7 with 
1.2 molar equivalents of allyltrimethylsilane, 15, in the presence 
BF3·Et2O, in CH3CN as solvent at ‒40°C  afforded,  after 
chromatographic purification, the allylated product 16 in 80% 
yield as a 1.3:1 mixture of diastereomers (Scheme 2). 
Although the lack of diastereofacial selectivity of the 
nucleophilic allylation was not a drawback because it opened the 
access to different stereoisomeric indolizidines, we decided to 
investigate if the protecting group of the oxygen side chain 
exerted any influence on the stereoselectivity of the allylation 
reaction. To this aim, the methoxymethyl (MOM), (+)-17, and 
benzyloxymethyl (BOM), (+)-18, derivatives of alcohol (‒)-5 
were prepared, converted into the corresponding N-acylaminals 
19 and 20, respectively, and the aminals subjected to the 
allylation reaction under identical conditions (Scheme 3). We 
observed that the allylation of both the MOM and BOM 
derivatives gave higher facial selectivity compared to the TBDPS 
analogue. However, the previous reduction of imides (+)-17 and 
(+)-18 proceeded in modest yields and no attempts were mad to 




Scheme 1. AAA of 1 and 2 and preparation of acylaminals 
(1’R)-7 and (1’R)-816 and synthetic plan for the 




Scheme 2. Nucleophilic allylation of (1’S)-7. 
 
 















The RCM of 16, performed with the mixture of diastereomers, 
in the presence of 5% molar second generation Grubbs catalyst 
(G-II) in CH2Cl2 at the reflux temperature, delivered the expected 
indolizidinone 23, which was isolated as a mixture of 
diastereomers in 92% yield (Scheme 4). This mixture was 
desilylated by treatment with Et3N·3HF in THF and the free 
alcohols 24 were separately isolated through purification by 
column chromatography on silica gel, furnishing theless polar 
isomer (+)-(5S,8aS)-24 in 34% yield and the more polar isomer 
(‒)-(5S,8aR)-24 in 42% yield. The relative configuration of these 
alcohols was established by X-ray diffraction analysis of the less 
polar isomer (Figure 2) that revealed the cis relationship between 
protons H-5 and H-8a. Each diastereomer of 24 was then 
separately re-silylated to afford (‒)-(5S,8aS)-23 and (‒)-(5S,8aR)-
23, in in 91% and 95% yield, respectively. 
Then, the allylation of the glutarimide derivative (1’S)-8 was 
undertaken (Scheme 5). In previous studies where (1’R)-8 
participated as the acceptor in a vinylogous Mannich reaction, we 
found that it was necessary to acetylate the hydroxyl group 
before generating the corresponding N-acyliminium ion, in order 
to circumvent the competitive elimination reaction leading to the 
enamide 26.16a Hence, (1’S)-8 was converted into the acetate 25 
by treatment with acetic anhydride in CH2Cl2, in the presence of 
dimetyhlaminopyridine (DMAP), and an excess triethylamine 
(TEA),18 which contributed to avoid the formation of the enamide 
26 in parallel with the desired acetylation. The acetate 25 was 
isolated and rapidly subjected to the allylation reaction under the 
above conditions. Unexpectedly, we observed the predominant 
formation of the enamide 26 instead of the desired allylation 
product 27. In view of that, we assayed other Lewis acids and 
conditions and found that the use of TMSOTf in CH2 l2 at 
−40°C produced diene 27 as a 30:1 mixture of diastereomers in 
79% overall yield for the two steps (acetylation/allyl tion). 
The RCM of 27, performed in the presence of 1% molar G-II 
in CH2Cl2 at the reflux temperature, after chromatographic 
purification, delivered the quinolizidine 28 as a unique isomer in 
96% yield. This yield may be raised up to 98% by increasing the 
catalyst amount to 10%. As before, the azabicycle 28 was treated 
with Et3N·3HF in THF to get the corresponding free alcohol 29, 
which relative configuration was established as 6S,9aS through 
an X-ray diffraction analysis (Figure 3). 
Among other possibilities, the new alcohols 24 and 29 were 
visualized as suitable intermediates for the preparation of 
azabicyclic dipeptide mimics. To this purpose it would be 
necessary to accomplish an electrophilic amination at the α-
carbonyl position and the oxidation of the primary lcohol to a 
carboxylic acid. Since the amination required the formation of an 
enolate under strongly basic conditions, we anticipated that it 
could be complicated by the presence of the relatively acidic 
allylic and α-nitrogen proton. Hence, we decided to hydrogenate 
the carbon-carbon double bond. The initial experiments with the 
TBDPS derivative (5R,8aR)-23, under 1 atm of H2 in the 
presence of Pd/C in THF or EtOAc, showed that this substrate 
was very sluggish to react and that the migration of the carbon-
carbon double bond leading to (8aS)-31 was a competitive 
process (Scheme 6, A). In methanol as the solvent, the 
hydrogenation was much faster but concomitant with partial 
desilylation. Luckily, the hydrogenation in MeOH using as 
starting substrates the two isomeric alcohols 24 instead of their 
TBDPS derivatives 23 (Scheme 6, B) furnished the 
corresponding indolizidones 32 in good yields. Then, the same 
conditions were applied to prepare quinolizidone (6S,9aR)-33 
from the corresponding alkene precursor. The α-amination of 
alcohols 24, 32 and 33 and silyl ether 30 was intended by 
treatment with three different sets of reagents: ButOK/nBuONO,19 
LDA/trisyl azide20 and LDA/di-tert-butyl azodicarboxylate,21 
leading to recovery of the starting material in thefirst case and to 
unidentified decomposition products in the other cases. 
 
 
Scheme 4. Preparation of indolizidinones 23 and 24. 
 
Figure 2. X-ray structure of alcohol (+)-(5S,8aS)-24. 
 
 
Scheme 5. Preparation of quinolizidinones 28 and 29. 
 














As an alternative, we decided to explore the application of the 
sequence developed for preparing indolizidines starting from the 
simple succinimide 1 to the amino-substituted substrate (‒)-34 
(Scheme 7), commercially available and readily prepa d in three 
steps from L-aspartic acid.22 This parallel sequence should thus 
involve the following consecutive steps: i) palladium catalyzed 
AAA, ii) O-silylation, iii) reduction to the acylaminal, iv) 
nucleophilic allylation, and v) RCM to form the indolizidine 
framework. Contrary to succinimide 1, the starting substrate (‒)-
34 is a chiral compound lacking any kind of symmetry. 
Consequently, it was particularly interesting to study the 
influence of the preexisting stereogenic centre on the 
stereoselectivity of the first allylation step, as well as on the 
regioselectivity of the reduction to the acylaminal from the imide. 
If the sequence could be successfully adapted to (‒)-34, 
desilylation and subsequent oxidation of the primary lcohol 
should furnish the targeted peptide. 
Initially, the AAA of (‒)-34 with butadiene monoxide (±)-3 
was assayed under the same conditions used for succinimide, 
namely with 0.4 mol% Pd (II), 1.2 mol% (1R,2R)-4 and 5 mol% 
Na2CO3 in dichloromethane at room temperature, but, 
surprisingly, in this case the starting material was recovered 
unchanged. The addition of DMF to the reaction medium, 
working at refluxing CH2Cl2, furnished the expected allylated 
product in a low 30% yield. Neither THF nor toluene as solvent, 
in both cases at the reflux temperature, led to any conversion of 
the substrate, but, when the reaction was performed in 1,2-
dichloroethane (DCE) at 60°C, after purification by column 
chromatography on silica gel, the desired olefin 35a was isolated 
in 68% yield,  [α]D −15.6 (c 1.04, CH2Cl2), apparently as a single 
diastereomer according to NMR analysis. Hence, the 1H-NMR 
spectrum of compound 35a, which was performed at 50°C to 
improve the resolution, showed only one set of signals, while the 
13C-NMR spectrum presented splitting of some signals, which 
was attributed to slow conformational equilibria relat d to the 
carbamate group and intramolecular hydrogen bonding. Since 
35a contains two stereogenic centres, the diastereomeric product 
ratio directly correlates with the stereoselectivity of the process. 
At this point, it was not possible to establish the relative 
configuration of 35a and we assumed that the absolute 
configuration of the new stereogenic centre was governed by the 
sense of chirality of the catalyst ligand and, hence, we tentatively 
assigned it as S. Considering that the parallel reaction with the 
parent succinimide 1 under optimized conditions proceeded in 
87% ee, we were intrigued by the apparent benefit that the pre-
existing stereogenic centre in succinimide (‒)-34 exerts on the 
stereoselectivity of the reaction and decided to investigate if this 
improvement was due to a matching effect between the sense of 
chirality of the catalyst and the substrate, or it was a consequence 
of the lower reactivity of (‒)-34, compared to the parent 
unsubstituted succinimide. To this aim, we assayed th  reaction 
of (‒)-34 with (±)-3 under identical conditions except for the use 
of the other enantiomer (1S,2S)-4 of the catalyst ligand (Scheme 
8). From this experiment, after chromatographic purification, we 
isolated the expected allylation product 35b in 73% yield, [α]D 
+14.6 (c 1.04, CH2Cl2), along with a minor quantity of the 
regioisomer (+)-41 (6%). To our surprise, despite the opposite 
sign of the optical rotation, both 1H- and 13C-NMR spectra of 35b 
showed identical signals to those of the former product 35a, 
isolated from the reaction in the presence of the ot r enantiomer 
of the catalyst ligand. 
This finding led us to consider the possibility that both 
isolated products 35a and 35b were actually mixtures of two 
diastereomers in different proportions, a hypothesis which was 
reinforced when the samples were analyzed by CHPLC. Thus, 
both chromatograms presented at least four peaks, some of which 
 
Scheme 7. Adjustment of the synthetic sequence to the 
preparation of azabicycles 40. 




Scheme 6. Hydrogenation of 23 and preparation of 














seemed to be common, in different relative intensities, but the 
complexity of these chromatograms prevented to infer the 
composition of the mixtures. In an attempt to solve this problem, 
the alcohols 35a and 35b were separately converted into the 
corresponding silyl ethers 36a and 36b, with the aim of 
suppressing the conformational complexity generated by the 
intramolecular hydrogen bonding. The silyl derivaties 36a and 
36b presented also identical NMR spectra, with splitting of some 
13C signals, but showed simpler chromatograms, each one 
consisting in three peaks with different relative intensities (Figure 
4). Analysis of these chromatograms, along with  one f a 
mixture of 36a and 36b in equal amounts, made evident that the 
two diastereomers (3S,1’R)-36 and (3S,1’S)-36 were present in 
both samples and that each diastereomer displays two peaks, 
attributable to the two rotational carbamate conformers, with a 
close retention time for one rotamer of each isomer. 
Since the conformational equilibrium of each diastereomer 
should not be affected by the presence of the other one, 
comparing the relative intensities of the peaks for each sample, it 
was possible to deduce its composition, which was roughly 88/12 
(de 76%) for 36a, coming from the reaction in the presence of the 
ligand (1R,2R)-4 and 21/79 (de 58%) for 36b, coming from the 
reaction in the presence of the ligand (1S,2S)-4. We can therefore 
conclude that the chirality of the substrate exerts a moderate 
influence on the stereochemical course of the reaction and that 
the stereoselectivity is mainly dictated by the sense of chirality of 
the catalyst ligand. 
The synthesis was continued from the silyl ether 36a (Scheme 
7). The regioselective reduction of the imide was accomplished 
by treatment with DIBALH in toluene at ‒78°C.23 The 
acylaminal 37, isolated in 67% yield as a mixture of isomers, was 
treated with allyltrimethylsilane in the presence of BF3·Et2O, 
furnishing a 1.6:1 mixture of epimeric dienes 38 in 78% overall 
yield. Any diene eventually derived from the minor diastereomer 
(12%) present in the starting material 36a could not be detected. 
The RCM of 38 was performed in refluxing CH2Cl2 in the 
presence of 5% G-II catalyst and, after chromatographic 
purification, afforded the two azabicyles (‒)-(2S,5S,8aR)-39 (less 
polar) and (‒)-(2S,5S,8aS)-39 (more polar) in 37% and 43% 
yield, respectively. NMR experiments on these compounds 
confirmed their connectivity, since in their 2D-COSY spectra the 
signal of H-8a is related to four saturated hydrogens (2H-1 and 
2H-8), but not to the proton next to the amino group (H-2). Their 
relative configuration was established after converting each 
isomer of 39 into the corresponding alcohol 40. Thus, a NOESY 
experiment with the alcohol 40 derived from the less polar 
isomer of the silyl ether 39 in C6D6 showed crossed peaks 
between the three protons attached to the stereogenic c tres, 
evidencing that H-2 (δ 4.25), H-5 (δ 4.04) and H-8a (δ 3.22) 
were in the same face of the bicyclic system, namely in a relative 
all cis configuration. Since the absolute configuration at C-2 was 
known to be S, according to the starting aspartic acid derivative, 
the absolute configuration of the new compounds 39 and 40 
could be unambiguously established, confirming the entative 
configuration assigned to the major diastereomer of alkene 35a, 
formed in the AAA of imide (‒)-34. 
With the two diastereomers of 40 in hands, the only remaining 
step to the target peptides was the oxidation of the primary 
alcohol to the corresponding carboxylic acid. This transformation 
was attempted with several reagents, including DMP, PCC, 
Swern reagent, Jones reagent,24 and NaIO4/RuCl3·3H2O,
25 under 
different conditions, leading always to decomposition products. 
Hence, we decided to undertake the hydrogenation of the carbon-
carbon double bond prior to the oxidation (Scheme 9). This 
transformation was accomplished in MeOH solution, under 2 atm 
of hydrogen, using Pd/C as the catalyst, and proceeded with 
concomitant hydrogenolysis of the carbamate, as expected. 
Without isolation of the intermediate, the amino group was re-
protected either as the benzyl- (Cbz) or the t rt-
butyloxycarbamate (Boc), furnishing the corresponding alcohols 
42 and 43, respectively, in good overall yields. Alcohol 
(2S,5S,8aS)-43 has been previously described and converted into 
the peptide mimic (2S,5S,8aS)-44 and its methyl ester.20 The 
alcohol oxidation of the Cbz derivatives 42, intended under 
various standard methods, revealed problematic, leading mainly 
to decomposition products instead of the expected carboxylic 
acids. However, the oxidation of the Boc derivative (2S,5S,8aR)-
 
 
Figure 4. CHPLC analysis of 36a and 36b, derived from the 
AAA of (‒)-34, in the presence of the ligand catalyst 
(1R,2R)-4 and (1S,2S)-4, respectively. CHPLC analyses of 
the synthetic samples 36a, 36b and their mixture in equal 
amounts remain constant over time. 
 
 















43 by treatment with Jones’ reagent delivered the known 
peptide surrogate (2S,5S,8aR)-44,26 in good yield. 
 
3. Conclusions 
We have developed an enantioselective approach to 
substituted indolizidine and quinolizidine frameworks, based on 
the introduction of two allylic residues over an imide substrate at 
a suitable distance, followed by a ring closing metathesis of the 
diene. The first allylic fragment is attached by means of a 
palladium mediated asymmetric N-alkylation and the second one 
through a nucleophilic addition to an acyliminium ion. By using 
the chiral succinimide (‒)-34 derived from aspartic acid, the 
general strategy has been applied to the synthesis of an 
indolizidine peptide mimic. It was observed that thepr existing 
stereogenic center of this substrate has a moderate influ nce on 
the stereoselectivity of the first allylation step, which is mainly 
determined by the sense of chirality of the catalys. 
 
4. Experimental section 
4.1. General remarks 
Commercially available reagents were used as received. The 
solvents were dried by distillation over the appropriate drying 
agents. All reactions were performed avoiding moisture by 
standard procedures and under nitrogen atmosphere. Flash 
column chromatography was performed using silica gel (230-400 
mesh). High-Performance Liquid Chromatography (HPLC) 
analyses were performed using a chromatograph coupled to a 
UV-visible array detector (at 214 nm) with a Daicel Chiralcel OD 
(25 x 0.46 cm) with a flow of 1 ml/min and 97:03 
hexane:isopropanol as mobile phase. 1H NMR and 13C NMR 
spectra were recorded at 250 and 62.5 MHz, 360 and 90 MHz, or 
400 and 101 MHz. Proton and carbon chemical shifts are 
reported in ppm (δ) (CDCl3, δ 7.26 for 1H; CDCl3, δ 77.2 for 13C; 
C6D6 δ 7.16 for 1H; δ 128.4 for 13C). NMR signals were assigned 
with the help of COSY, HSQC, HMBC, and NOESY 
experiments. Melting points were determined on hot stage and 
are uncorrected. Optical rotations were measured at 22 ± 2°C. 
4.2. (S)-1-(1-Hydroxybut-3-en-2-yl)pyrrolidine-2,5-dione ((‒)-5) 
A mixture of π-allylpalladium chloride dimer (11.8 mg, 0.03 
mmol), (1R,2R)-4 (81 mg, 0.10 mmol), sodium carbonate (43 
mg, 0.40 mmol) and succinimide, 1 (797 mg, 8.05 mmol) was 
purged with nitrogen for 1 h. Dry CH2Cl2 (100 mL) was added 
and the mixture was stirred at room temperature for 10 min. 
Then, butadiene monoepoxide, 3 (640 µL, 8.00 mmol) was 
added and the resulting mixture was efficiently stirred under 
nitrogen for 14 h. After that time, the reaction mixture was 
filtered through Celite®, washing with ethyl acetate, and the 
filtrate concentrated under vacuum. The residue was purified by 
flash column chromatography (hexanes/ethyl acetate, from 5:1 to 
2:1) to give (−)-5 (1.14 g, 6.76 mmol, 84% yield) as a clear oil in 
83% enantiomeric excess (determined by CHPLC analysis, 
iPrOH/hexane, 10:90): [α]D −32.8 (c 1.90, CH2Cl2). Other 
physical and spectroscopic data of (−)-5 were identical to those 
previously described for (+)-5.16 
4.3. (5RS)-1-[(S)-1-(tert-Butyldiphenylsilyloxy)but-3-en2-yl]-5-
hydroxypyrrolidin-2-one ((1’S)-7) 
4 .3.1. Si ly la t ion of  (−)- 5  
In a 250 mL Schlenk flask equipped with magnetic stirring, 
under nitrogen atmosphere, alcohol (−)-5 (1.35 g, 7.98 mmol) 
was dissolved in anhydrous CH2Cl2 (60 mL). After cooling to 
0°C, imidazole (2.72 g, 39.90 mmol) was added, followed by 
TBDPSCl (4.1 mL, 15.96 mmol). The cooling bath was removed 
and the mixture was stirred at room temperature overnight. The 
solvent was evaporated under vacuum and replaced by ethyl
acetate (50 mL). The resulting mixture was stirred vigorously for 
1 h and the insoluble fine white powder (imidazole·HCl) filtered 
through Celite®. The filtrate was concentrated under vacuum and 
then purified by flash column chromatography (hexanes/ethyl 
acetate, from 9:1 to 3:2) to give a residue, which was crystallized 
from 2-propanol, furnishing the expected silylated derivative 
(2.18 g, 5.35 mmol, 67% yield) of >98% ee (determined by 
CHPLC analysis, iPrOH/hexane, 10:90): [α]D +14.4 (c 1.30, 
CH2Cl2). The physical and spectroscopic data of this compound 
were identical to those previously described for its enantiomer.16 
4.3.2. Reduct ion  
A solution of LiBEt3H in THF (1M, 7.3 mL, 7.30 mmol) was 
added dropwise to a solution of the previous intermediat  (1.99 g, 
4.88 mmol) in dry THF (25 mL), under nitrogen atmosphere at 
−78°C, and the reaction mixture, monitored by TLC 
(hexanes/ethyl acetate, 1:1), was stirred at the same te perature 
for 45 min. Keeping the temperature at −78°C saturated aqueous 
NaHCO3 (40 mL) and H2O2 (30%, 10 mL) were added, and the 
mixture was allowed to warm slowly to room temperature and 
then stirred for one additional hour. After filtration through 
Celite®, the solution was extracted with CH2Cl2 (4x30 mL), and 
the combined organic extracts were dried over anhydrous Na2SO4 
and concentrated under vacuum. The oily residue was purified by 
flash chromatography (hexanes/ethyl acetate, from 4:1 to 1:1) to 
give a mixture of epimers (1’S)-7 (1.70 g, 4.15 mmol, 85% yield) 
as a colourless oil. The physical and spectroscopic data of this 




In a 250 mL Schlenk flask equipped with magnetic stirring 
and nitrogen atmosphere, a solution of  (1’S)-7 (982 mg, 2.40 
mmol) in anhydrous CH3CN (50 mL) was cooled down to 
−40°C. To the cold solution was added allyltrimethylsilane (420 
µL, 2.64 mmol) and then, dropwise, BF3·Et2O (610 µL, 4.80 
mmol). The reaction, monitored by TLC (hexanes/ethyl acetate, 
3:2), was finished in 1 h. Then, saturated aqueous NaHCO3 (100 
mL) was added and the mixture was allowed to warm up to room 
temperature. After the extraction with CH2Cl2 (4x50 mL), the 
combined organic extracts were dried over anhydrous Na2SO4 
and concentrated under vacuum. The residue was purified by 
flash column chromatography (hexanes/ethyl acetate, from 4:1 to 
1:2) to give a 1.3:1 mixture of (5R)- and (5S)-16 (832 mg, 1.92 
mmol, 80% yield) as a yellow oil: Rf = 0.4 (hexanes/ethyl 
acetate, 3:2); IR (ATR) 3073, 2932, 2858, 1687, 1428, 1259, 
1110  cm-1; 1H NMR (400 MHz, CDCl3) Isomer A (5R) and B 
(5S) δ 7.67 (m, 4HA + 4HB), 7.40 (m, 6HA + 6HB), 6.11 (ddd, J = 
17.4, 10.5, 7.1 Hz, 1HB), 5.90 (ddd, J = 17.1, 10.5, 6.6 Hz, 1HA), 
5.66 (m, 1HA + 1HB), 5.12 (m, 4HA + 4HB), 4.55 (m, 1HA), 4.21 
(dd, J = 10.2, 8.4 Hz, 1HB), 4.08 (m, 1HB), 3.97 (m, 1HA + 1HB), 
3.75 (m, 2HA + 1HB), 2.49-1.98 and 1.75 (m) (6HA + 6HB), 1.07 
(s, 9HB), 1,06 (s, 9HA);
 13C NMR (101 MHz, CDCl3) δ 175.6, 
175.0, 135.5, 134.4, 133.5, 133.4, 133.2, 129.7, 127.7, 127.6, 
118.4, 118.2, 118.0, 117.6, 63.7, 62.9, 59.5, 59.3, 57.0, 39.4, 
38.7, 30.4, 30.1, 26.8, 26.7, 23.9, 23.8, 19.1; HRMS m/z (ESI+) 
calcd for [C27H35NO2SiNa
















In a 25 mL Schlenk flask equipped with magnetic stirring, 
under nitrogen atmosphere, alcohol (−)-5 (246 mg, 1.45 mmol) 
was dissolved in anhydrous CH2Cl2 (3.8 mL). After cooling to 
0°C, DIPEA (1.6 mL, 9.2 mmol), DMAP (57 mg, 0.47 mmol) 
and MOMBr (185 µL, 2.27 mmol) were consecutively added. 
The cooling bath was removed, the mixture was allowed to warm 
to room temperature, and then it was heated at reflux overnight. 
The solvent was evaporated under vacuum and replaced by Et2O 
(10 mL). The solution was washed with brine (10 mL), the 
organic phase was dried over anhydrous Na2SO4 and 
concentrated under vacuum and the residue (278 mg) was 
purified by flash column chromatography (ethyl acett ) to 
furnish (+)-17 (238 mg, 1.12 mmol, 77% yield) as oil: Rf= 0.3 
(hexanes/ethyl acetate, 1:1); [α]D +15 (c 0.01, CH2Cl2); IR (ATR) 
2922, 2852, 1697, 1383, 1193, 1147, 1107 cm-1; 1H NMR (400 
MHz, CDCl3) δ 6.05 (ddd, J = 17.5, 10.2, 7.6 Hz, 1H), 5.24 (m, 
2H), 4.85 (m, 1H), 4.55 (m, 2H), 4.09 (t, J = 10.1 Hz, 1H); 3.72 
(dd, J = 10.6, 5.7 Hz, 1H), 3.30 (s, 3H), 2.68 (s, 4H); 13C NMR 
(101 MHz, CDCl3) δ 176.7, 131.4, 119.6, 96.4, 65.7, 55.6, 54.4, 
28.0; HRMS (ESI+) calcd for [C10H15NO4Na




In a 25 mL Schlenk flask equipped with magnetic stirring, 
under nitrogen atmosphere, alcohol (−)-5 (144 mg, 0.85 mmol) 
was dissolved in anhydrous CH2Cl2 (5 mL). After cooling to 0°C, 
BOMCl (240 µL, 173 mmol) and DIPEA (220 µL, 1.26 mmol) 
were added. The cooling bath was removed and the mixture, 
monitored by TLC (hexanes/ethyl acetate, 1:1), was stirred at 
room temperature overnight. The solution was diluted with Et2O 
(10 mL) and washed with water (3x30 mL) and brine (30 mL). 
The organic phase was dried over anhydrous Na2SO4 and 
concentrated under vacuum and the residue (276 mg) was 
purified by flash column chromatography (ethyl acett ) to 
furnish (+)-18 (240 mg, 0.83mmol, 97% yield) as oil: Rf= 0.5 
(hexanes/ethyl acetate, 1:1);  [α]D +12 (c 0.01, CH2Cl2); IR 
(ATR) 2920, 1774, 1698, 1383, 1254, 1195, 1111, 1040 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.32 (m, 5H), 6.07 (ddd, J = 17.9, 
10.3, 7.7 Hz, 1H), 5.27 (m, 2H), 4.88 (m, 1H), 4.70 (m, 2H), 4.55 
(s, 2H); 4.17 (t, J = 10.1 Hz, 1H), 3.80 (dd, J = 10.3, 5.6 Hz, 1H), 
2.66 (s, 4H); 13C NMR (101 MHz, CDCl3) δ 177.0, 137.6, 131.4, 
128.4, 127.8, 127.7, 119.6, 94.5, 69.9, 66.0, 54.1, 28.1; HRMS 
(ESI+) calcd for [C16H19NO4Na
+]: 312.1212, found: 312.1204. 
4.7. (5RS)-5-Hydroxy-1-[(S)-1-methoxymethoxybut-3-en-2-
yl]pyrrolidin-2-one (19) 
A solution of LiBEt3H in THF (1M, 3.8 mL, 3.80 mmol) was 
added dropwise to a solution of (+)-17 (490 mg, 2.30 mmol) in 
dry THF (20 mL), under nitrogen atmosphere at −78°C, and the 
reaction mixture, monitored by TLC (hexanes/ethyl acet te, 1:1), 
was stirred at the same temperature for 2 h. Keeping the 
temperature at −78°C, saturated aqueous NaHCO3 (24 mL) and 
H2O2 (30%, 5.5 mL) were added, and the mixture was allowed to 
warm slowly to room temperature and then stirred for one 
additional hour. The solution was concentrated and then filtered 
through a small pad of silica gel, washing with ethyl acetate. The 
solvent was removed under vacuum, water (50 mL) was added to 
the residue and then extracted with CH2 l2 (4x40 mL). The 
organic extracts were dried over anhydrous Na2SO4 and 
concentrated under vacuum. The crude product was purified by 
flash column chromatography (hexanes/ethyl acetate, from 1:1 to 
1:9) to give a 1.6:1 mixture of epimers (1’S)-19 (146 mg, 0.68 
mmol, 30% yield) as a colourless oil: Rf = 0.1 (hexanes/ethyl 
acetate, 1:1); IR (ATR) 3348, 2934, 1663, 1419, 1280, 1148, 
1108, 1036 cm-1; 1H NMR (400 MHz, CDCl3) Isomer A (major) 
and B (minor) δ 6.03 (ddd, J = 17.4, 10.5, 6.9 Hz, 1HB), 5.89 
(ddd, J = 16.9, 10.6, 6.0 Hz, 1HA), 5.23 (m, 3HA + 3HB), 4.82 (m, 
1HA), 4.63 (m, 2HA + 2HB), 4.51 (br s, 1HA), 4.42 (m, 1HB), 3.96 
(m, 1HB), 3.77 (m, 2HA), 3.70 (dd, J = 10.2, 4.0 Hz, 1HB), 3.35 
(s, 3HA), 3.33 (s, 3HB), 2.63 (m, 2HA), 2.28 (m, 2HB), 2.23 (m, 
2HB), 2.10 (m, 2HA); 
13C NMR (101 MHz, CDCl3) Isomer A 
(major) and B (minor)  δ 175.5 (A) and 174.9 (B), 133.9 (B) and 
132.5 (A), 118.8 (A) and 118.0 (B), 96.7 (A) and 96.5 (B), 83.6 
(B) and 80.5 (A), 68.5 (A) and 66.8 (B), 55.8 (A+B), 55.6 (B) 
and 52.7 (A), 29.2 (B) and 28.7 (A), 28.1 (B) and 27.8 (A); 
HRMS m/z (ESI+) calcd for [C10H16NO4Na




A solution of LiBEt3H in THF (1M, 5.2 mL, 5.20 mmol) was 
added dropwise to a solution of (+)-18 (798 mg, 2.76 mmol) in 
dry THF (50 mL), under nitrogen atmosphere at −78°C, and the 
reaction mixture, monitored by TLC (hexanes/ethyl acet te, 1:1), 
was stirred at the same temperature for 1.5 h. Keeping the 
temperature at −78°C, saturated aqueous NaHCO3 (25 mL) and 
H2O2 (30%, 5.5 mL) were added, and the mixture was allowed to 
warm slowly to room temperature and then stirred for one 
additional hour. The solution was concentrated and then filtered 
through a small pad of silica gel, washing with ethyl acetate. The 
solvent was removed under vacuum, water (70 mL) was added to 
the residue, and then it was extracted with CH2 l2 (4x50 mL). 
The combined organic extracts were dried over anhydrous 
Na2SO4 and concentrated under vacuum. The crude product was 
purified by flash column chromatography (hexanes/ethyl acetate, 
from 1:1 to 1:4) to give a 1.5:1 mixture of epimers (1’S)-20 (273 
mg, 0.94 mmol, 34% yield) as a colourless oil: Rf = 0.1 
(hexanes/ethyl acetate, 1:1); IR (ATR) 3342, 2921, 1663, 1453, 
1418, 1279, 1164, 1107, 1039 cm-1; 1H NMR (400 MHz, CDCl3) 
Isomer A (major) and B (minor) δ 7.34 (m, 5HA + 5HB), 6.06 
(ddd, J = 17.0, 10.4, 6.7 Hz, 1HB), 5.91 (ddd, J = 17.5, 10.9, 6.4 
Hz, 1HA), 5.26 (m, 3HA + 3HB), 4.86 (m, 1HA), 4.79 (m, 2HA + 
2HB), 4.60 (s, 2HA + 2HB), 4.49 (s, 1HA), 4.39 (m, 1HB), 4.06 (m, 
1HB), 3.85 (m, 2HA), 2.66 (m, 2HA), 2.28 (m, 2HA), 2.07 (m, 
4HB); 
13C NMR (101 MHz, CDCl3) Isomer A (major) and B 
(minor)  δ 175.5/174.9 (A/B), 133.3 (A+B), 137.0 (A+B), 133.8 
(B) and 132.5 (A), 128.5 (A+B), 127.8 (A+B),  119.0 (A) and 
118.2 (B), 94.8 (A+B), 83.8 (B) and 80.4 (A), 70.1 (A+B), 68.7 
(A) and 67.2 (B), 56.0 (B) and 52.9 (A), 29.3 (B) and 28.8 (A), 
28.0 (B) and 27.8 (A); HRMS m/z (ESI+) calcd for 
[C16H21NO4Na
+]: 314.1363, found: 314.1363. 
4.9. (5RS)-5-Allyl-1-[(S)-1-methoxymethoxybut-3-en-2-
yl]pyrrolidin-2-one (21) 
In a 25 mL Schlenk flask equipped with magnetic stirring and 
nitrogen atmosphere, a solution of  (1’S)-19 (16 mg, 0.07 mmol) 
in anhydrous CH3CN (1.5 mL) was cooled down to −40°C. To 
the cold solution was added allyltrimethylsilane (14.5 µL, 0.09 
mmol) and then, dropwise, BF3·Et2O (24.5 µL, 0.19 mmol). The 
reaction, monitored by TLC (hexanes/ethyl acetate, 2:3), was 
finished in 4 h. Then, saturated aqueous NaHCO3 (5 mL) was 
added and the mixture was allowed to warm up to room 
temperature. After the extraction with CH2Cl2 (4x5 mL), the 
combined organic extracts were dried over anhydrous Na2SO4 
and concentrated under vacuum. The residue was purified by 
flash column chromatography (hexanes/ethyl acetate, from 3:7 to 
1:9) to give a 1.9:1 mixture of (5R)- and (5S)-21 (9 mg, 0.04 
mmol, 50% yield) as a yellow oil: Rf = 0.2 (hexanes/ethyl 
acetate, 2:3); IR (ATR) 3079, 2931, 1681, 1417, 1257, 1151, 
1111, 1039  cm-1; 1H NMR (360 MHz, CDCl3) Isomer A (major) 














(ddd, J = 17.0, 10.4, 6.6 Hz, 1HA), 5.71 (m, 1HA + 1HB), 5.18 
(m, 4HA + 4HB), 4.61 (m, 2HA + 2HB),  4.50 (m, 1HA), 4.32 (m, 
1HB), 3.89 (m, 2HA + 2HB), 3.35 (s, 3HA + 3HB), 2.49-1.72 
(complex, 6HA + 6HB); 13C NMR (90 MHz, CDCl3) δ 175.7, 
175.2, 134.5, 133.4, 118.5, 117.5, 96.4, 67.9, 66.8, 58.7, 57.3, 
56.4, 55.4, 55.1, 39.2, 38.9, 30.3, 30.1, 23.8; HRMS m/z (ESI+) 
calcd for [C13H21NO3Na
+]: 262.1419, found: 262.1412. 
4.10. (5RS)-5-Allyl-1-[(S)-1-benzyloxymethoxybut-3-en-2-
yl]pyrrolidin-2-one (22) 
In a 25 mL Schlenk flask equipped with magnetic stirring and 
nitrogen atmosphere, a solution of  (1’S)-20 (42 mg, 0.15 mmol) 
in anhydrous CH3CN (2.7 mL) was cooled down to −40°C. To 
the cold solution was added allyltrimethylsilane (28 µL, 0.18 
mmol) and then, dropwise, BF3·Et2O (49 µL, 0.39 mmol). The 
reaction, monitored by TLC (hexanes/ethyl acetate, 2:3), was 
finished in 4 h. Then, saturated aqueous NaHCO3 (9 mL) was 
added and the mixture was allowed to warm up to room 
temperature. After the extraction with CH2Cl2 (4x9 mL), the 
combined organic extracts were dried over anhydrous Na2SO4 
and concentrated under vacuum. The residue was purified by 
flash column chromatography (hexanes/ethyl acetate, from 3:2 to 
3:7) to give a 1.9:1 mixture of (5R)- and (5S)-22 (24 mg, 0.08 
mmol, 53% yield) as a yellow oil: Rf = 0.3 (hexanes/ethyl 
acetate, 2:3); IR (ATR) 2927, 2879, 1681, 1414, 1255, 1167, 
1110, 1040  cm-1; 1H NMR (400 MHz, CDCl3) Isomer A (major) 
and B (minor) δ 7.34 (m, 5HA +5HB), 6.08 (ddd, J = 17.3, 10.6, 
7.0 Hz, 1HB), 5.95 (ddd, J = 17.2, 10.4, 6.7 Hz, 1HA), 5.72 (m, 
1HA + 1HB), 5.19 (m, 4HA + 4HB), 4.77 (m, 2HA + 2HB),  4.60 
(m, 2HA + 2HB), 4.51 (m, 1HA), 4.30 (m, 1HB), 3.97 (m, 2HA + 
1HB), 3.74 (m, 1HA + 2HB), 2.49-1.72 (complex, 6HA + 6HB);
 13C 
NMR (101 MHz, CDCl3) δ 175.6, 175.2, 134.5, 137.8, 134.5, 
133.3, 128.6, 127.8, 118.5, 117.8, 94.7, 69.7, 68.0, 67.1, 58.8, 
57.3, 56.5, 55.1, 39.2, 38.9, 30.3, 30.1, 23.9; HRMS m/z (ESI+) 
calcd for [C19H25NO3Na
+]: 338.1732, found: 338.1727. 
4.11. (5S,8aRS)-5-(tert-Butyldiphenylsilyloxy)methyl-1,5,8,8a-
tetrahydroindolizin-3(2H)-one (23) 
In a 250 mL Schlenk flask, equipped with magnetic strring 
and nitrogen atmosphere, a solution of 16 (654 mg, 1.51 mmol) 
in anhydrous CH2Cl2 (150 mL) was warmed up to the reflux 
temperature  and, then, 2nd generation Grubbs catalyst (65 mg, 
0.075 mmol) was added in 3 portions (one per hour). The mixture 
was heated at reflux overnight. After cooling down to room 
temperature, the resulting mixture was filtered through a small 
pad of silica gel, washing with ethyl acetate. The filtrate was 
concentrated under vacuum and the residue purified by flash 
column chromatography (hexanes/ethyl acetate, from 3:2 to 1:9) 
to give a 1.2:1 mixture of (5S,8aR)- and (5S,8aS)-23 (563 mg, 
1.39 mmol, 92% yield): Rf = 0.3 (hexanes/ethyl acetate, 1:1); IR 
(ATR) 3070, 3044, 2929, 2856, 1684, 1421, 1109 cm-1; HRMS 
m/z (ESI+) calcd for [C25H31NO2SiNa]: 428.2022, found: 
428.2015. Other characterization data of these compounds are 
given below. 
4.12. (5S,8aR)- and (5S,8aS)-5-Hydroxymethyl-1,5,8,8a-
tetrahydroindolizin-3(2H)-one (24) 
In a 250 mL Schlenk flask, equipped with magnetic strring 
and nitrogen atmosphere, a solution of a mixture of (5S,8aR)- and 
(5S,8aS)-23 (360 mg, 0.89 mmol) in anhydrous THF (15 mL) 
was heated to the reflux temperature. After the addition of 
Et3N·3HF, (0.87 mL, 5.34 mmol), the mixture was stirred under 
reflux overnight. After cooling, the mixture was diluted with 
CH2Cl2 (10 mL) and saturated aqueous NaHCO3 (10 mL) was 
added. The layers were separated and the aqueous one extracted 
with CH2Cl2 (4x20 mL). The combined organic extracts were 
dried over anhydrous Na2SO4 and concentrated under vacuum, 
and the residue was purified by flash column chromatgr phy 
(from hexanes/ethyl acetate, 1:1, to ethyl acetate nd then 
chloroform/methanol, 9:1) to give (5S,8aS)-24 (51 mg, 0.31 
mmol, 34% yield), which was less polar, and (5S,8aR)-24 (63 
mg, 0.38 mmol, 42% yield), which was more polar. (5S,8aS)-24: 
Rf = 0.2 (ethyl acetate); [α]D +62.3 (c 1.35, CH2Cl2); IR (ATR): 
3352, 3050, 2930, 2857, 1700, 1669, 1648, 1417, 1268, 1105 cm-
1;  1H NMR (360 MHz, C6D6) δ 6.50 (m, 1H), 5.32 (ddt, J = 10.4, 
6.4, 2.1 Hz, 1H), 5.08 (m, 1H), 4.00 (m, 1H), 3.80 (m, 2H), 2.71 
(m, 1H), 1.94 (ddd, J = 10.3, 6.0, 2.0 Hz, 1H), 1.77 (m, 1H), 
1.52-1.25 (m, 3H), 0.80 (m, 1H); 13C NMR (90 MHz, C6D6) δ 
177.5, 126.6, 125.9, 67.7, 60.2, 56.3, 32.7, 31.2, 26.7; HRMS 
(ESI+) calcd for [C9H13NO2Na
+]: 190.0844, found: 190.0840. 
(5S,8aR)-24: Rf = 0.1 (ethyl acetate); [α]D −211.4 (c 1.20, 
CH2Cl2); IR (ATR): 3355, 2926, 1662, 1644, 1423, 1265, 1079 
cm-1;  1H NMR (360 MHz, C6D6) δ 5.39 (m, 2H), 4.59 (m, 1H), 
3.70 (m, 2H), 3.58 (m, 1H), 3.17 (m, 1H), 1.98 (m, 2H), 1.52 (m, 
2H), 1.31 (m, 1H), 0.87 (m, 1H);  13C NMR (90 MHz, C6D6) δ 
175.8, 126.2, 125.7, 66.1, 54.0, 51.4, 32.8, 30.5, 25.9; HRMS 
(ESI+) calcd for [C9H13NO2Na
+]: 190.0844, found: 190.0843. 
4.13. (5S,8aR)-5-(tert-Butyldiphenylsilyloxy)methyl-1,5,8,8a-
tetrahydroindolizin-3(2H)-one ((5S,8aR)-23) 
In a 10 mL Schlenk flask, equipped with magnetic stirring and 
nitrogen atmosphere, (5S,8aR)-24 (50 mg, 0.30 mmol) was 
dissolved in anhydrous CH2Cl2 (2 mL). After cooling to 0°C, 
imidazole (82 mg, 1.20 mmol) and TBDPSCl (0.16 mL, 0.6 
mmol) were added. The cooling bath was removed and the 
mixture was stirred at room temperature overnight. Te reaction 
mixture was concentrated under vacuum and the residu 
dissolved in ethyl acetate (5 mL). After vigorous stirring for 1 h, 
the mixture was filtered through Celite®, washing with ethyl 
acetate. The filtrate was concentrated under vacuum and the 
residue purified by flash column chromatography (from 
hexanes/ethyl acetate, 1:1, to ethyl acetate) to give (5S,8aR)-23 
(115 mg, 0.30 mmol, 95% yield): Rf = 0.3 (hexanes/ethyl acetate, 
1:1); [α]D −161 (c 0.94, CH2Cl2);  1H NMR (400 MHz, C6D6) δ 
7.74 (m, 4H), 7.23 (m, 6H), 5.59 (m, 2H), 4.63 (m, 1H), 3.90 (dd, 
J = 9.8, 5.4 Hz, 1H), 3.71 (dd, J = 9.8, 4.3 Hz, 1H), 3.40 (m, 1H), 
2.01 (m, 2H), 1.75-1.25 (m, 3H), 1.13 (s, 9H), 0.98 (m, 1H); 13C 
NMR (101 MHz, C6D6) δ 173.4, 136.6, 134.7, 134.4, 130.7, 
127.1, 126.2, 65.9, 52.4, 52.0, 32.8, 30.3, 27.8, 25.9, 20.1. 
4.14. (5S,8aS)-5-(tert-Butyldiphenylsilyloxy)methyl-1,5,8,8a-
tetrahydroindolizin-3(2H)-one ((5S,8aS)-23) 
The same procedure starting from (5S,8aS)-24 (50 mg, 0.30 
mmol) furnished (5S,8aS)-23 (110 mg, 0.27 mmol, 91% yield): 
Rf = 0.3 (hexanes/ethyl acetate, 1:1); [α]D −64  (c 1.45, CH2Cl2);  
1H NMR (250 MHz, C6D6) δ 7.93 (m, 4H), 7.35 (m, 6H), 5.83 
(m, 2H), 4.43 (m, 2H), 4.24 (m, 1H), 2.98 (m, 1H), 2.14 (ddt, J 
=16.7, 9.3, 1.2 Hz, 1H), 1.96 (m, 1H) 1.84 (m, 2H), 1.52 (m, 1H), 
1.29 (s, 9H), 1.12 (m, 1H); 13C NMR (101 MHz, C6D6) δ 174.3, 
135.6, 133.7, 129.5, 125.0, 63.9, 54.4, 54.2, 31.8, 30.6, 26.7, 
26.5, 19.2. 
4.15. (S)-1-(1-Hydroxybut-3-en-2-yl)piperidine-2,6-dione ((‒)-6) 
A mixture of π-allylpalladium chloride dimer (72 mg, 0.20 
mmol), (1R,2R)-4 (474 mg, 0.57 mmol), sodium carbonate (246 
mg, 2.32 mmol) and glutarimide, 2, (2.60 g, 22.99 mmol) was 
purged with nitrogen for 1 h. Dry CH2Cl2 (180 mL) was added 
and the mixture was stirred at room temperature for 10 min. 
Then, butadiene monoepoxide, 3, (1.8 mL, 22.37 mmol) was 














nitrogen for 14 h. After that time, the reaction mixture was 
filtered through Celite®, washing with CH2Cl2 (120 mL) and 
then ethyl acetate (250 mL), and the filtrate concentrated under 
vacuum. The residue was purified by flash column 
chromatography (hexanes/ethyl acetate, from 1:1 to 2:3) to give 
(−)-6 (4.03 g, 22.00 mmol, 99% yield) as a clear oil in 95% 
enantiomeric excess (determined by CHPLC analysis, 
iPrOH/hexane, 3:1): [α]D −23.3 (c 1.40, CH2Cl2). Other physical 
and spectroscopic data of (−)-6 were identical to those previously 
described for (+)-6.16 
4.16. (6RS)-1-[(S)-1-(tert-Butyldiphenylsilyloxy)but-3-en2-yl]-6-
hydroxypiperidin-2-one ((1’S)-8) 
4 .16.1. Si ly la t ion of  (+) -6  
 
In a 250 mL Schlenk flask equipped with magnetic stirring, 
under nitrogen atmosphere, alcohol (−)-6 (1.90 g, 10.37 mmol) 
was dissolved in anhydrous CH2Cl2 (100 mL). After cooling to 
0°C, imidazole (3.54 g, 52.06 mmol) was added, followed by 
TBDPSCl (3.2 mL, 12.31 mmol). The cooling bath was removed 
and the mixture was stirred at room temperature overnight. The 
solvent was evaporated under vacuum and replaced by ethyl
acetate (70 mL). The resulting mixture was stirred vigorously for 
1 h and the insoluble fine white powder (imidazole·HCl) filtered 
through Celite®. The filtrate was concentrated under vacuum and 
then purified by flash column chromatography (hexanes/ethyl 
acetate, from 9:1 to 3:2) to give a residue, which was crystallized 
from 2-propanol, furnishing the expected silylated derivative 
(3.99 g, 9.46 mmol, 91% yield): [α]D +16.7 (c 1.00, CH2Cl2). The 
physical and spectroscopic data of this compound were identical 
to those previously described for its enantiomer.16 
4.16.2. Reduct ion  
  A solution of LiBEt3H in THF (1M, 11.5 mL, 11.5 mmol) 
was added dropwise to a solution of the previous intermediate 
(3.02 g, 7.17 mmol) in dry THF (28 mL), under nitrogen 
atmosphere at −78°C, and the reaction mixture, monitored by 
TLC (hexanes/ethyl acetate, 1:1), was stirred at the same 
temperature for 45 min. Keeping the temperature at −78ºC 
saturated aqueous NaHCO3 (60 mL) and H2O2 (30%, 12 mL) 
were added, and the mixture was allowed to warm slowly to 
room temperature and then stirred for one additional hour. After 
filtration through Celite®, the solution was extracted with 
CH2Cl2 (4x30 mL), and the combined organic extracts were dri d 
over anhydrous Na2SO4 and concentrated under vacuum. The 
oily residue was purified by flash chromatography (hexanes/ethyl 
acetate, from 3:1 to 1:1) to give a mixture of epimers (1’S)-8 
(2.65 g, 6.27 mmol, 87% yield) as a colourless oil. The physical 
and spectroscopic data of this product were identical o those 
previously described for (1’R)-8.16 
4.17. (6R)- and (6S)-6-Allyl-1-[(S)-1-(tert-
butyldiphenylsilyloxy)but-3-en-2-yl]piperidin-2-one (27) 
In a 50 mL Schlenk flask equipped with magnetic stirring and 
nitrogen atmosphere, a solution of  (1’S)-8 (1.375 g, 3.25 mmol) 
was dissolved in anhydrous CH2Cl2 (17 mL). After cooling to 
0°C, DMAP (198 mg, 1.62 mmol), acetic anhydride (0.77 mL, 
8.12 mmol) and Et3N (1.13 mL, 8.12 mmol) were added. The 
cooling bath was removed and the mixture was stirred at room 
temperature overnight. The reaction mixture was diluted with 
saturated aqueous NaHCO3 solution (15 mL) and water (15 mL) 
and then extracted with CH2Cl2 (4x15 mL). The combined 
organic extracts were dried over anhydrous Na2SO4 and 
concentrated under vacuum. The remaining crude product 25 was 
used in the next step without further purification. To this end, in a 
50 mL Schlenk flask equipped with magnetic stirring and 
nitrogen atmosphere, a solution of the crude ester 25 in 
anhydrous CH2Cl2 (17 mL) was cooled to −40°C, followed by the 
addition of allyltrimethylsilane (1.0 mL, 6.5 mmol) and then, 
dropwise, TMSOTf (0.90 mL, 4.88 mmol). The reaction, 
monitored by TLC (hexanes/EtOAc, 1:1) was finished in 1.5 h. 
After that time, the reaction mixture was cooled to −78°C, 
saturated aqueous NaHCO3 (30 mL) was added and the mixture 
was allowed to warm up to room temperature. After extraction 
with CH2Cl2 (4x30 mL), the combined organic extracts were 
dried over anhydrous Na2SO4 and concentrated under vacuum. 
The residue was purified by flash column chromatography 
(hexanes/ethyl acetate, from 4:1 to 1:2) to give a 30:1 mixture of 
(6S)- and (6R)-27 (1.05 g, 2.34 mmol, 79% yield) as a yellow oil: 
Rf = 0.7 (hexanes/ethyl acetate, 1:1); IR (ATR) 3071, 2931, 
2857, 1637, 1427, 1107 cm-1; 1H NMR (250 MHz, CDCl3) (6S)-
27 (major) δ 7.68 (m, 4H), 7.41 (m, 6H), 6.22 (ddd, J = 17.4, 
10.6, 6.8 Hz, 1H), 5.68 (m, 1H), 5.11 (m, 4H), 4.29 (td, J = 10.0, 
4.0 Hz, 1H), 3.86 (m, 2H), 3.43 (m, 1H), 2.55-2.10 (complex, 
4H), 1.87-1.59 (complex, 4H), 1.08 (s, 9H); (6R)-27 (minor) 
significant signals δ 6.06 (m, 1H), 5.18 (m, 4H), 4.01 (m, 2H); 
13C NMR (63 MHz, CDCl3) (6S)-27 δ 169.9, 135.7, 135.3, 134.6, 
133.7, 133.5, 129.8, 127.8, 117.9, 117.1, 66.0, 64.2, 59.0, 37.7, 
32.6, 27.0, 25.7, 19.2, 16.3; HRMS m/z (ESI+) calcd for 
[C28H37NO2SiNa
+]: 470.2491, found: 470.2491. 
4.18. (6S,9aS)-6-[(tert-Butyldiphenylsilyloxy)methyl]-
1,2,3,6,9,9a-hexahydroquinolizin-4(4H)-one (28) 
To a solution of a 30:1 mixture of (6S)- and (6R)-27 (2.74 g, 
6.12 mmol) in anhydrous and previously degassed CH2Cl2 (227 
mL), 2nd generation Grubbs catalyst (51 mg, 0.06 mmol) was 
added and the mixture was heated at reflux overnight. After 
cooling down to room temperature, the reaction mixture was 
filtered through a short pad of silica gel, washing with Et2O. The 
filtrate was concentrated under vacuum and the crude material 
was purified by flash column chromatography (hexanes/Et2O, 
from 9:1 to 1:1) to furnish 28 (2.47 g, 5.88 mmol, 96% yield) as a 
unique isomer: Rf = 0.38 (3:1, Et2O/hexanes); [α]D = -85.8 (c 
1.00, CHCl3); IR (ATR) 2928, 2854, 1668, 1612, 1406, 1095 cm
-
1; 1H NMR (400 MHz, CDCl3) δ 7.67(m, 4H), 7.39 (m, 6H), 6.06 
(ddd, J = 9.8, 6.7, 2.4 Hz, 1H), 5.98 (ddd, J = 9.8, 5.0, 2.7 Hz, 
1H), 4.65 (m, 1H), 3.89 (m, 2H), 3.30 (tt, J = 11.0, 3.1 Hz, 1H), 
2.41 (m, 2H), 2.16 (m, 2H), 1.89 (m, 2H), 1.75 (m, 1H), 1.51 (m, 
1H), 1.05 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 171.3, 135.7, 
133.9, 133.8, 129.6, 128.0, 127.7, 127.6, 127.0, 65.3, 55.0, 53.9, 
32.9, 32.0, 31.1, 27.0, 20.8, 19.4; HRMS (ESI+) calcd for 
[C26H33NO2Si
+]: 419.2281, found: 419.2287. 
4.19. (6S,9aS)-6-Hydroxymethyl-1,2,3,6,9,9a-
hexahydroquinolizin-4(4H)-one (29) 
In a 50 mL Schlenk flask, equipped with magnetic stirring 
and nitrogen atmosphere, a solution of 28 (264 mg, 0.63 mmol) 
in anhydrous THF (10 mL) was heated to the reflux temp rature. 
After the addition of Et3N·3HF, (0.62 mL, 5.34 mmol), the 
mixture was stirred under reflux overnight. The resulting cold 
mixture was diluted with CH2Cl2 (10 mL) and saturated aqueous 
NaHCO3 (10 mL) was added. The layers were separated and the 
aqueous one extracted with CH2Cl2 (4x8 mL). The combined 
organic extracts were dried over anhydrous Na2SO4, concentrated 
under vacuum, and the residue was purified by flash column 
chromatography (from hexanes/ethyl acetate, 1:1, to e hyl 
acetate) to give 29 (107 mg, 0.59 mmol, 94% yield): Rf = 0.1 
(ethyl acetate);  [α]D −35.5 (c 1.30, CH2Cl2); IR (ATR) 3339, 
2983, 1612, 1410, 1265, 1034 cm-1; 1H NMR (250 MHz, CDCl3) 
δ 6.03 (m, 1H), 5.80 (m, 1H), 4.64 (m, 1H), 3.78 (dd, J = 11.3, 














(dd, J = 8.3, 5.5 Hz, 2H), 2.15 (m, 2H), 1.93 (m, 2H), 1.79 (m,
1H), 1.57 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 173.3, 126.9, 
126.6, 67.2, 56.7, 55.6, 32.5, 31.3, 30.5, 20.0; HRMS (ESI+) 
calcd for [C10H15NO2Na





In a 10 mL Schlenk flask equipped with magnetic stirring, 
(6S,8aR)-23 (136 mg, 0.34 mmol) was dissolved in THF (5 mL) 
and Pd/C (15 mg) was added. The flask was sealed up by a
septum, connected to a balloon filled with H2 and the mixture 
was stirred at room temperature overnight. After that time, the 
solution was filtered through Celite®, washing with etyl acetate, 
and then concentrated under vacuum. The residue was filtered 
through a short pad of silica gel, to furnish two fractions, one 
containing pure (8aS)-31 (28 mg, 0.07 mmol, 20% yield) and 
another one containing a mixture (69 mg) of the starting material, 
(6S,8aR)-23, and (5S,8aS)-30. Repeated chromatography allowed 
the isolation of an analytical pure sample of (5S,8aS)-30 (11 mg). 
(5S,8aS)-30: Rf = 0.6 (ethyl acetate);  [α]D −34.1 (c 0.55, 
CH2Cl2); IR (ATR) 2929, 2855, 1684, 1426, 1109 cm
-1; 1H NMR 
(400 MHz, CDCl3) δ 7.66 (m, 4H), 7.43 (m, 6H), 4.39 (m,1H), 
3.67 (dd, J = 10.4, 6.7 Hz, 2H), 3.40 (dtd, J = 10.9, 7.2, 3.5 Hz, 
1H), 2.31 (m, 2H), 2.10 (m, 1H), 2.00-1.37 (complex,7H), 1.07 
(s, 9H); 13C NMR (101 MHz, CDCl3) δ 173.8, 135.6, 133.4, 
133.2, 129.6, 127.6, 61.7, 54.2, 48.9, 33.5, 30.2, 26.8, 25.7, 24.1, 
19.2, 19.1; HRMS (ESI+) calcd for [C25H33NO2SiNa
+]: 430.2178, 
found: 430.2176. (8aS)-31: Rf = 0.3 (hexanes/ethyl acetate, 1:1);  
[α]D −17.9 (c 1.40, CH2Cl2); IR (ATR) 2928, 2855, 1694, 1657, 
1405, 1261, 1111 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.71 (m, 
4H), 7.41 (m, 6H), 5.43 (br s, 1H), 4.96 (br d, J = 14.9 Hz, 1H), 
4.79 (br d, J = 14.9 Hz, 1H), 3.62 (m, 1H), 2.41 (ddd, J = 17.0, 
11.0, 9.7 Hz, 1H), 2.25 (m, 3H), 2.04 (br d, J =12.5 Hz, 1H), 1.58 
(m, 3H), 1.09 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 172.5, 
136.9, 135.5, 133.6, 129.5, 127.6, 105.9, 62.4, 57.1, 31.2, 29.9, 
26.9, 25.9, 22.7, 19.3; HRMS (ESI+) calcd for 
[C25H31NO2SiNa
+]: 428.2022, found: 428.2016. 
4.21. (5S,8aR)-5-Hydroxymethylhexahydroindolizin-3(2H)-one 
((5S,8aR)-32) 
In a 10 mL Schlenk flask equipped with magnetic stirring, 
(6S,8aS)-24 (50 mg, 0.30 mmol) was dissolved in methanol (2 
mL) and Pd/C (5 mg) was added. The flask was sealed up by a 
septum, connected to a balloon filled with H2 and the mixture 
was stirred at room temperature overnight. After that time, the 
solution was filtered through Celite®, washing with etyl acetate, 
and then concentrated under vacuum. The residue was filtered 
through a short pad of silica gel, to furnish (5S,8aR)-32 (38 mg, 
0.22 mmol, 75% yield): Rf = 0.2 (ethyl acetate);  [α]D −7.0 (c 
1.40, CH2Cl2); IR (ATR) 3306, 2936, 2859, 1655, 1420, 1267, 
1061 cm-1; 1H NMR (250 MHz, CDCl3) δ 5.33 (dd, J = 8.9, 6.2 
Hz, 1H), 3.85 (m, 2H), 3.44 (m, 1H), 3.15 (m, 1H), 2.42 (m, 2H), 
2.22 (m, 1H), 2.00-1.22 (complex, 7H); 13C NMR (101 MHz, 
CDCl3) δ 175.5, 63.7, 60.8, 60.4, 33.1, 31.4, 27.9, 25.1, 23.5; 
HRMS (ESI+) calcd for [C9H15NO2Na




The same procedure starting from (6S,8aR)-24 (20 mg, 0.12 
mmol), furnished (5S,8aS)-32 (18 mg, 0.11 mmol, 89% yield): Rf 
= 0.1 (ethyl acetate);  [α]D −31.5 (c 1.00, CH2Cl2); IR (ATR) 
3365, 2937, 2854, 1657, 1420, 1265, 1056 cm-1; 1H NMR (400 
MHz, CDCl3) δ 4.31 (m, 1H), 3.70 (dd, J = 11.0, 9.0 Hz, 1H), 
3.61 (m, 2H), 2.76 (br s, 1H), 2.37 (m, 2H), 2.21 (m, 1H), 1.97-
1.40 (complex, 6H), 1.15 (m, 1H); 13C NMR (101 MHz, CDCl3) 
δ 175.6, 61.6, 53.9, 49.9, 33.3, 30.3, 25.8, 24.2, 19.4; HRMS 
(ESI+) calcd for [C9H15NO2Na
+]: 192.1000, found: 192.0996. 
4.23. (6S,9aR)-6-Hydroxymethyloctahydroquinolizin-4(4H)-one 
((6S,9aR)-33) 
The same procedure starting from (6S,9aS)-29 (50 mg, 0.27 
mmol), furnished (6S,9aR)-33 (39 mg, 0.21 mmol, 79% yield): Rf 
= 0.2 (ethyl acetate);  [α]D −80.0 (c 0.60, CH2Cl2); IR (ATR) 
3371, 2940, 2872, 1603, 1410, 1343, 1050 cm-1; 1H NMR (250 
MHz, CDCl3) δ 4.94 (dd, J = 7.5, 5.8 Hz, 1H), 3.82 (m, 2H), 3.52 
(m, 1H), 3.39 (m, 1H), 2.42 (m, 2H), 2.08-1.38 (complex, 10H); 
13C NMR (101 MHz, CDCl3) δ 171.1, 65.3, 62.0, 57.5, 33.3, 
31.7, 29.7, 25.9, 21.3, 18.5; HRMS (ESI+) calcd for 
[C10H17NO2H
+]: 184.1338, found: 184.1360. 
4.24. Benzyl {(S)-1-[(RS)-1-hydroxybut-3-en-2-yl]-2,5-
dioxopyrrolidin-3-yl]carbamate (35) and benzyl (S,E)-[1-(4-
hydroxybut-2-en-1-yl)-2,5-dioxopyrrolidin-3-yl]carbamate (41) 
A mixture of π-allylpalladium chloride dimer (6.4 mg, 0.02 
mmol), (1R,2R)-4 (44 mg, 0.05 mmol), sodium carbonate (25 
mg, 0.05 mmol) and (−)-(3S)-34 (720 mg, 2.90 mmol) was 
purged with nitrogen for 1 h. Dry 1,2-dichloroethane (20 mL) 
was added and the mixture was stirred at room temperatur  for 10 
min. Then, butadiene monoepoxide, 3, (230 µL, 2.90 mmol) was 
added and the resulting mixture was warmed up to 60ºC and 
stirred under nitrogen overnight. After that time, the reaction 
mixture was filtered through Celite®, washing with ethyl acetate, 
and concentrated under vacuum. The residue was purified by 
flash column chromatography (hexanes/ethyl acetate, from 3:1 to 
1:2) to give 35a (627 mg, 1.97 mmol, 68% yield) as a clear oil:
Rf = 0.6 (ethyl acetate);  [α]D −15.6 (c 1.04, CH2Cl2); IR (ATR) 
3343, 3058, 2949, 1696, 1518, 1391, 1263, 1196 cm-1; 1H NMR 
(400 MHz, CDCl3, 323K) δ 7.37-7.28 (m, 5H), 6.10-5.97 (m, 
1H), 5.80 (br s, 1H), 5.31-5.22 (m, 2H), 5.10 (br s, 2H), 4.87-
4.74 (m, 1H), 4.33-4.16 (m, 1H), 4.15-4.07 (m, 1H), 3.78-3.67 
(m, 1H), 3.21 (m, 1H), 3.08-2.72 (complex, 3H); 13C NMR (101 
MHz, CDCl3, 323K) δ 176.1/176.0, 174.5/174.4, 156.0, 
135.7/135.6, 130.9/130.8, 128.5, 128.3, 128.2, 128.0, 119.3, 67.5, 
61.5, 57.2/56.9, 49.9/49.8, 35.6; HRMS (ESI+) calcd for
[C16H18N2O5]: 318.1216, found: 318.1207. The same reaction 
starting from (−)-(3S)-34 (190 mg, 0.77 mmol) in the presence of 
(1S,2S)-4 (2 mg, 2.5 µmol) furnished 35b (178 mg, 0.60 mmol, 
73% yield) and 41 (14.5 mg, 0.05 mmol, 6% yield). 35b: [α]D 
+14.6 (c 1.04, CH2Cl2); the rest of physical and spectroscopic 
data are identical to those described for 35a, isolated from the 
previous reaction. The optical rotation values of 36a and 36b 
remain constant over time. 41: Rf = 0.35 (ethyl acetate);  [α]D 
+5.1 (c 0.39, CH2Cl2); IR (ATR) 3333, 2924, 2854, 2362, 2343, 
1703, 1528, 1401, 1263, 1172 cm-1; (400 MHz, CDCl3, 323K) 
major conformer δ 7.32 (m, 5H), 5.85 (m, 1H), 5.48 (br s, 2H), 
5.10 (m, 2H), 4.34-4.21 (complex, 5H), 4.11 (m, 1H), 3.10 (m, 
1H), 2.80 (m, 1H); 13C NMR (101 MHz, CDCl3, 323K) δ 175.0, 
173.6, 155.5, 134.2, 128.8, 128.6, 128.4, 124.0, 123.7, 67.5, 58.0, 





Imidazole (65.4 mg, 0.96 mmol) and TBDPSCl (130 µL, 0.51 
mmol) were added to a solution of the alcohol 35a (100 mg, 0.32 
mmol), obtained in the presence of (1R,2R)-4, in anhydrous 














overnight at room temperature. After that time, it was 
concentrated under vacuum and the residue dissolved in ethyl 
acetate (2 mL). Then, the solution was filtered through Celite®, 
washing with ethyl acetate. The filtrate was concentrated under 
vacuum and the residue was purified by flash column 
chromatography (hexanes/ethyl acetate, from 4:1 to 1:1) to afford 
36a (150 mg, 0.27 mmol, 85% yield): Rf = 0.26 (hexanes/ethyl 
acetate, 3:1);  IR (ATR) 2929, 2856, 1709, 1510, 1390, 1264, 111 
cm-1; 1H NMR (400 MHz, CDCl3, 323 K) δ 7.65 (m, 4H), 7.40 
(m, 11H), 6.02 (m, 1H), 5.38 (m, 1H), 5.24 (m, 2H), 5.14 (s, 2H), 
4.89 (m, 1H), 4.29 (m, 2H), 3.86 (ddd, J = 10.4, 5.9, 2.8 Hz, 1H), 
3.06 (m, 1H), 2.69 (m, 1H), 1.05 (s, 9H); 13C NMR (101 MHz, 
CDCl3, 323 K) δ 175.3/175.2, 173.7/173.6, 156.0, 136.1, 135.7, 
135.7, 133.5, 133.4, 133.3, 131.3/131.1, 130.0, 128.7, 128.5, 
128.3, 127.9, 119.8/119.7, 67.6, 62.7/62.3, 57.0/569, 50.4/50.3, 
36.6, 27.0, 19.3; HRMS (ESI+) calcd for [C32H36N2O3SiNa
+]: 
579.2291, found: 579.2286. The same reaction starting from the 
alcohol 35b (110 mg, 0.35 mmol), obtained in the presence of 
(1S,2S)-4, furnished 36b (158 mg, 0.28 mmol, 82% yield): the 
spectroscopic data of this sample were identical to th se 
described for 36a. CHPLC analysis showed that 36a and 36b 




In a 100 mL Schlenk flask equipped with magnetic stirring 
and nitrogen atmosphere, (−)-36a (1.42 g, 2.55 mmol) was 
dissolved in anhydrous toluene (15 mL). The solution was cooled 
down to −78°C, DIBAL-H (1M in toluene, 3.8 mL, 3.8 mmol) 
was added dropwise and the reaction mixture, monitored by TLC 
(hexanes/ethyl acetate, 1:1), was stirred at the same te perature 
for 1 h. Keeping the temperature at −78°C, saturated queous 
potassium sodium tartrate (15 mL) was added, the mixture was 
allowed to warm slowly to room temperature, and then stirred for 
30 min. After filtration through Celite®, the solution was 
extracted with CH2Cl2 (4x25 mL), the combined organic extracts 
were dried over anhydrous Na2SO4 and concentrated under 
vacuum. The oily residue was purified by flash column 
chromatography (hexanes/ethyl acetate, from 4:1 to 1:1) to give a 
mixture of isomers 37 (953 mg, 1.71 mmol, 67% yield) as a 
colourless oil: Rf = 0.5 (hexanes/ethyl acetate, 1:1); IR (ATR) 
3309, 2930, 2856, 1685, 1521, 1427, 1264, 1109 cm-1; 1H NMR 
(250 MHz, CDCl3) δ 7.68 (m, 4H), 7.42 (m, 11H), 6.30-5.87 
complex, 2H), 5.40-4.90 (complex, 6H), 4.57 (m, 1H),  4.07 (m, 
1H), 3.89 (m, 2H), 2.76 (m, 1H), 1.95 (br d, J = 14.4 Hz,1H), 
1.09 (s) and 1.07 (s) (9H); 13C NMR (63 MHz, CDCl3) δ 171.9, 
156.9, 156.7, 136.1, 136.0, 134.6, 130.4, 129.0, 128.6, 128.5, 
128.3, 119.3, 118.6, 81.7, 81.4, 67.6, 60.8, 58.3, 57.9, 51.6, 27.3, 
27.2, 21.5, 19.7, 19.6; HRMS (ESI+) calcd for 
[C32H38N2O5SiNa




In a 100 mL Schlenk flask equipped with magnetic stirring 
and nitrogen atmosphere, a solution of 37 (1.30 g, 2.33 mmol) in 
anhydrous CH2Cl2 (30 mL) was cooled down to −40°C. To the 
cold solution was added allyltrimethylsilane (450 µL, 2.80 mmol) 
and then, dropwise, BF3·Et2O (740 L, 5.82 mmol). The 
reaction, monitored by TLC (hexanes/ethyl acetate, 3:2), was 
finished in 1.5 h. Then, saturated aqueous NaHCO3 (25 mL) was 
added and the mixture was allowed to warm up to room 
temperature. After the extraction with CH2Cl2 (4x20 mL), the 
combined organic extracts were dried over anhydrous Na2SO4 
and concentrated under vacuum. The residue was purified by 
flash column chromatography (hexanes/ethyl acetate, from 4:1 
to 1:1) to give an 1.6:1 mixture of epimers 38 (1.06 g, 1.82 
mmol, 78% yield) as a yellow oil: Rf = 0.8 (hexanes/ethyl 
acetate, 1:1); IR (ATR) 2930, 2856, 1686, 1499, 1239, 1109 cm-
1; 1H NMR (250 MHz, CDCl3) δ Isomer A (major) and B (minor) 
δ 7.66 (m, 4H), 7.40 (m, 11H), 6.07 (ddd, J = 17.4, 10.4, 7.1 Hz, 
1HB), 5.89 (ddd, J = 17.3, 10.5, 6.9 Hz, 1HA), 5.67 (m, 1H), 5.27-
5.05 (complex, 7H), 4.52-3.60 (complex, 4H), 2.68-1.80 
(complex, 4H), 1.08 (s) and 1,07 (s) (9H); 13C NMR (101 MHz, 
CDCl3) δ 172.2, 171.7, 156.4, 136.3, 135.5, 133.4, 133.2, 133.1, 
133.0, 132.9, 132.4, 129.9, 129.8, 128.5, 128.0, 127.7, 119.1, 
118.9, 118.6, 118.4, 66.8, 63.8, 62.7, 57.9, 57.3, 51.6, 51.4, 38.5, 
38.0, 33.3, 26.8, 19.1; HRMS (ESI+) calcd for [C35H41N2O4Si
+]: 
581.2836, found: 581.2852. 
4.28. Benzyl [(2S,5S,8aR)- and [(2S,5S,8aS)-5-(tert-
butyldiphenylsilyloxy)methyl-3-oxo-1,2,3,5,8,8a-
hexahydroindolizin-2-yl]carbamate (39) 
In a 250 mL Schlenk flask, equipped with magnetic strring 
and nitrogen atmosphere, a solution of the mixture of pimers 38 
(700 mg, 1.20 mmol) in anhydrous CH2Cl2 (100 mL) was 
warmed up to the reflux temperature  and, then, 2nd generation 
Grubbs catalyst (51 mg, 0.06 mmol) was added in 3 portions (one 
per hour). The mixture was heated at reflux overnight. After 
cooling down to room temperature, the resulting mixture was 
filtered through a small pad of silica gel, washing with ethyl 
acetate. The filtrate was concentrated under vacuum and the 
residue purified by flash column chromatography (hexanes/ethyl 
acetate, from 4:1 to 1:2) to give by elution order (2S,5S,8aR)-39 
(246 mg, 0.44 mmol, 37% yield)  and (2S,5S,8aS)-39 (283 mg, 
0.51 mmol, 43% yield). (2S,5S,8aR)-39: Rf = 0.6 (hexanes/ethyl 
acetate, 1:1);  [α]D −31 (c 1.95, CH2Cl2); IR (ATR) 3296, 2930, 
2889, 1683, 1528, 1427, 1256, 1109 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.66 (m, 4H), 7.38 (m, 11H), 6.01 (m, 1H), 5.85 (m, 
1H), 5.28 (br s, 1H), 5.12 (m, 2H), 4.32 (dd, J = 9.6, 5.6 Hz, 1H), 
4.22 (m, 1H), 4.10 (m, 2H), 3.74 (m, 1H), 2.31 (m, 2H), 2.08 (m, 
2H), 1.04 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 171.4, 156.2, 
136.1, 135.5, 133.5, 133.4, 129.6, 128.5, 128.1, 128.0, 127.5, 
127.3, 125.8, 66.9, 62.5, 54.9, 53.5, 52.0, 31.7, 29.6, 26.7, 19.3; 
HRMS (ESI+) calcd for [C33H37N2O4SiH
+]: 554.2601, found: 
554.2620. (2S,5S,8aS)-39: Rf = 0.4 (hexanes/ethyl acetate, 1:1);  
[α]D −69 (c 2.10, CH2Cl2); IR (ATR) 3304, 2929, 2856, 1685, 
1513, 1427, 1239, 1110 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.68 
(m, 4H), 7.41 (m, 11H), 5.92 (ddd, J =10.1, 5.2, 2.9 Hz, 1H), 
5.75 (m, 1H), 5.39 (br s, 1H), 5.15 (s, 2H), 4.53 (m, 1H), 4.31 (m, 
1H), 3.90-3.70 (complex, 3H), 2.40 (m, 1H), 2.20 (m, 1H), 2.03 
(complex, 2H), 1.09 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 
170.5, 156.4, 136.3, 135.6, 135.5, 133.2, 133.1, 129.8, 129.7, 
128.5, 128.1, 128.0, 127.7, 126.1, 125.8, 66.9, 65.0, 2.2, 51.8, 
49.4, 30.5, 29.6, 26.8, 19.2; HRMS (ESI+) calcd for 
[C33H37N2O4SiH
+]: 554.2601, found: 554.2612. 
4.29. Benzyl [(2S,5S,8aR)-5-hydroxymethyl-3-oxo-1,2,3,5,8,8a-
hexahydroindolizin-2-yl]carbamate ((2S,5S,8aR)-40  
In a 50 mL Schlenk flask, equipped with magnetic stirring 
and nitrogen atmosphere, a solution of (2S,5S,8aR)-39 (283 mg, 
0.51 mmol) in anhydrous THF (15 mL) was heated to the reflux 
temperature. After the addition of Et3N·3HF, (500 µL, 3.06 
mmol), the mixture was stirred under reflux overnight. After 
cooling, the resulting mixture was diluted with CH2Cl2 (10 mL) 
and aqueous saturated aqueous NaHCO3 (10 mL), the layers were 
separated and the aqueous one extracted with CH2Cl2 (4x10 mL). 
The combined organic extracts were dried over anhydrous 
Na2SO4, concentrated under vacuum, and the residue was 
purified by flash column chromatography (hexanes/ethyl acetate, 














87% yield): Rf = 0.4 (ethyl acetate);  [α]D +16.8 (c 1.35, 
CH2Cl2); IR (ATR) 3295, 2924, 1675, 1645, 1533, 1454, 1242, 
1040 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.37 (m, 5H), 5.90 (m, 
1H), 5.59 (m, 1H), 5.51 (d, J = 9.5 Hz, 1H), 5.12 (s, 2H), 4.35 
(m, 1H), 4.22 (m, 1H), 3.83 (d, J = 5.1 Hz, 2H), 3.75 (m, 1H), 
2.38-2.10 (complex, 4H); 13C NMR (101 MHz, CDCl3, 323K) δ 
172.8, 156.8, 136.7, 129.0, 128.6, 128.5, 127.1, 126.2, 67.6, 64.6, 
60.3, 54.5, 52.6, 33.3, 31.9; HRMS (ESI+) calcd for 
[C17H20N2O4
+]: 316.1423, found: 316.1403. 
4.30. Benzyl [(2S,5S,8aS)-5-hydroxymethyl-3-oxo-1,2,3,5,8,8a-
hexahydroindolizin-2-yl]carbamate ((2S,5S,8aS)-40  
The same procedure starting from (2S,5S,8aS)-39 (90 mg, 
0.21 mmol) furnished (2S,5S,8aS)-40 (54 mg, 0.17 mmol, 82% 
yield): Rf = 0.2 (ethyl acetate);  [α]D −67.5 (c 1.10, CH2Cl2); IR 
(ATR) 3297, 2923, 1673, 1649, 1531, 1454, 1255, 1057 cm-1; 1H 
NMR (400 MHz, CDCl3, 323K) δ 7.32 (m, 5H), 6.12 (m, 1H), 
5.87 (m,1H), 5.62 (m, 1H), 5.10 (s, 2H), 4.46 (m, 1H), 4.23 (m, 
1H), 3.79 (m, 2H), 3.57 (m, 1H), 3.38 (m, 1H: OH), 2.28-1. 5 
(complex, 4H); 13C NMR (101 MHz, CDCl3, 323K) δ 171.7, 
156.3, 136.3, 128.3, 127.9, 126.4, 124.5, 124.4, 66.9, 63.6, 53.2, 
52.1, 49.2, 32.9, 31.5; HRMS (ESI+) calcd for [C17H20N2O4
+]: 
316.1423, found: 316.1413. 
4.31. Benzyl [(2S,5S,8aR)-5-hydroxymethyl-3-
oxooctahydroindolizin-2-yl]carbamate, ((2S,5S,8aR)-42) 
A solution of (2S,5S,8aR)-40 (38 mg, 0.12 mmol) in MeOH 
(2 mL) stirring at room temperature was hydrogenated in the 
presence of Pd/C (10%, 4 mg) at 2 atm for 20 h. After that time, 
the solution was filtered through Celite®, washing with ethyl 
acetate, and the filtrate concentrated under vacuum. To the 
residue were added K2CO3 (33 mg, 0.24 mmol) and 1,4-
dioxane/H2O (1:1, 2 mL). The mixture was cooled down to 0ºC, 
CbzCl (19 µL, 0.13 mmol) was added and the resulting solution 
was stirred at room temperature overnight. Then, the solution 
was diluted with H2O (5 mL) and extracted with CH2Cl2 (4x3 
mL). The combined organic extracts were dried over anhydrous 
Na2SO4 and concentrated under vacuum. Purification of the 
residue by flash column chromatography (from hexane/ethyl 
acetate, 3:1 to ethyl acetate) furnished (2S,5S,8aR)-42 (30 mg, 
0.09 mmol, 78% yield): Rf = 0.3 (ethyl acetate);  [α]D +3.7 (c 
1.65, CH2Cl2); IR (ATR) 3289, 2938, 2869, 1672, 1534, 1454, 
1262, 1055 cm-1; 1H NMR (400 MHz, CDCl3, 323K) δ 7.37 (m, 
5H), 5.28 (br s, 1H), 5.14 (s, 2H), 4.31 (m, 1H), 3.91 (m, 2H), 
3.46 (m, 1H), 3.23 (m, 1H), 2.32 (br t, J = 12.3 Hz, 1H), 2.15 (dt, 
J = 12.3, 8.9 Hz, 1H), 1.97 (m, 1H), 1.82 (m, 1H), 1.67-1.23 
(complex, 4H); 13C NMR (101 MHz, CDCl3, 323K) δ 170.8, 
156.1, 136.2, 128.4,128.0, 127.9, 67.0, 62.9, 61.3, 57.9, 52.7, 
32.9, 31.9, 27.56, 23.84; HRMS (ESI+) calcd for [C17H22N2O4
+]: 
318.1580, found: 318.1586. 
4.32. Benzyl [(2S,5S,8aS)-5-hydroxymethyl-3-
oxooctahydroindolizin-2-yl]carbamate, ((2S,5S,8aS)-42) 
The same procedure starting from (2S,5S,8aS)-40 (20 mg, 
0.06 mmol), furnished (2S,5S,8aS)-42 (14 mg, 0.04 mmol, 74% 
yield): Rf = 0.1 (ethyl acetate);  [α]D −13.7 (c 0.70, CH2Cl2); IR 
(ATR) 3306, 2936, 2858, 1712, 1665, 1533, 1454, 1239, 1043 
cm-1; 1H NMR (400 MHz, CDCl3, 323K) δ 7.36 (m, 5H), 6.46 (br 
s) and (5.98 br s) (1H), 5.12 (m, 2H), 4.40-4.25 (complex), 4.17 
(m), 3.90-3.60 (complex) and 3.59 (dt, J = 11.8, 5.1 Hz) (5H), 
2.92 (m, 1H), 2.17 (m, 2H), 1.86-1.48 (complex, 5H), 1.16 (m, 
1H); 13C NMR (101 MHz, CDCl3, 323K) δ 171.7, 156.3, 136.3, 
128.3, 127.9, 66.9, 61.1, 60.8, 52.1, 51.6, 50.9, 33.3, 33.2, 32.9, 





A solution of (2S,5S,8aR)-40 (38 mg, 0.12 mmol) in MeOH 
(2 mL) stirring at room temperature was hydrogenated in the 
presence of Pd/C (10%, 4 mg) at 2 atm for 20 h. After that time, 
the solution was filtered through Celite®, washing with ethyl 
acetate, and the filtrate concentrated under vacuum. To the 
residue were added K2CO3 (25 mg, 0.18 mmol) and 1,4-
dioxane/H2O (1:1, 2 mL). The mixture was cooled down to 0°C, 
(Boc)2O (30 µL, 0.13 mmol) was added and the resulting solution 
was stirred at room temperature overnight. Then, the solution 
was diluted with H2O (3 mL) and extracted with CH2Cl2 (4x2 
mL). The combined organic extracts were dried over anhydrous 
Na2SO4 and concentrated under vacuum. Purification of the 
residue by flash column chromatography (from hexane/ethyl 
acetate, 3:1 to ethyl acetate) furnished (2S,5S,8aR)-43 (29 mg, 
0.10 mmol, 86% yield): Rf = 0.3 (ethyl acetate);  [α]D +13.0 (c 
1.00, CH2Cl2); IR (ATR) 3399, 2938, 2106, 1679, 1450, 1055 
cm-1; 1H NMR (250 MHz, CDCl3) δ 5.04 (br s, 1H), 4.28 (m, 
1H), 3.91 (dd, J =  9.4, 7.8 Hz, 1H), 3.86 (dd, J =  9.4, 3.9 Hz, 
1H), 3.43 (m, 1H), 3.25 (m, 1H), 2.29 (m. 1H), 2.12 (m, 1H), 
1.92 (dm, J = 12.5 Hz, 1H), 1.78 (dm, J = 12.5 Hz, 1H), 1.63-
1.22 (complex) and 1.44 (s) (13H); 13C NMR (101 MHz, CDCl3) 
δ 171.5, 156.0, 80.2, 63.1, 61.4, 58.1, 52.6, 33.3, 32.0, 28.5, 27.7, 
24.1; HRMS (ESI+) calcd for [C14H24N2O4




The same procedure starting from (2S,5S,8aS)-40 (38 mg, 
0.06 mmol), furnished (2S,5S,8aS)-4320 (29 mg, 0.10 mmol, 86% 
yield): Rf = 0.3 (ethyl acetate); 1H NMR (400 MHz, CDCl3) δ 
5.60 (br s) and 5.46 (br s (1H), 4.35 (m, 1H), 4.02 (m, 1H), 3.88 
(m, 1H), 3.79 (m, 1H), 3.58 (m, 1H), 2.16 (m, 1H), 2.05 (m, 1H), 
1.87 (m, 1H), 1.74-1.50 (complex, 6H), 1.42 (s, 9H); 13C NMR 
(101 MHz, CDCl3) ) δ 172.2, 156.3, 80.4, 61.5, 52.3, 52.0, 51.0, 
33.8, 33.3, 29.8, 28.6, 24.7, 20.2. 
4.35. (2S,5S,8aR)-2-(tert-Butoxycarbonylamino)-3-
oxooctahydroindolizine-5-carboxylic acid, ((2S,5S,8aR)-44) 
Jones reagent was prepared by dissolving 2 g of chromium 
trioxide in 2 mL of concentrated sulfuric acid and adding distilled 
water to bring the total volume to 10 mL. In a 10 mL Schlenk 
flask equipped with magnetic stirring, alcohol (2S,5S,8aR)-43 (11 
mg, 0.04 mmol) was dissolved in acetone (1 mL). Then, Jones 
reagent was added (0.5 mL) and the mixture was stirred at room 
temperature for 2 h. After that time, the reaction mixture was 
diluted with saturated aqueous NaHCO3 (2 mL) and extracted 
with CH2Cl2 (3x2 mL). Then, the aqueous layer was acidified 
with 10% HCl to pH = 1 and extracted again with CH2 l2 (4x2 
mL). The combined organic extracts were dried over anhydrous 
Na2SO4 and concentrated under vacuum to furnish (2S,5S,8aR)-
4426 (10 mg, 0.03 mmol, 86% yield): Rf = 0.2 (ethyl acetate); 1H 
NMR (400 MHz, CDCl3) δ 5.37 (m, 1H), 4.78 (m, 1H), 4.23 (m, 
1H), 3.90 (m, 1H), 3.62 (m, 1H), 2.20 (m, 2H), 2.07 (m, 1H), 
1.97 (dt, J = 13.2, 3.2 Hz, 1H), 1.89 (m, 1H), 1.72 (m, 1H), 1.56 
(m, 1H), 1.45 (s, 9H), 1.36 (dd, J = 12.4, 3.8 Hz, 2H); 13C NMR 
(101 MHz, CDCl3) δ 172.9 , 172.2 , 156.0 , 80.3 , 58.2 , 56.9 , 
51.9 , 33.5 , 31.0 , 28.5 , 27.9 , 22.6; HRMS (ESI+) calcd for 
[C14H22N2O5Na
+]: 321.1426, found: 321.1421. 
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